Gyre Therapeutics, Inc. Investing Cash Flow
Gyre Therapeutics, Inc. (GYRE) reported Investing Cash Flow of $6.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-07
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $9.76M, a 620.61% increase year-over-year.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$3.06M, a 255.31% decline year-over-year.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $1.85M.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$5.64M.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$474.00K.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$19.88M.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$19.76M.
- Gyre Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$13.81M, a 128.67% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $6.70M 10-Q · filed 2026-08-07 | $8.55M derived: sum of 3 quarters · filed 2026-08-07 | $2.91M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | -$3.06M 10-Q · filed 2026-05-08 | -$1.21M derived: sum of 2 quarters · filed 2026-05-08 | -$6.85M derived: sum of 3 quarters · filed 2026-05-08 | -$5.50M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$3.79M derived: sum of 2 quarters · filed 2026-03-13 | -$2.44M derived: sum of 3 quarters · filed 2026-08-07 | -$474.00K 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | -$5.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$4.29M derived: sum of 2 quarters · filed 2026-08-07 | -$2.32M 10-Q · filed 2025-11-07 | -$4.33M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $3.32M 10-Q · filed 2026-08-07 | -$1.07M 10-Q · filed 2025-08-11 | $1.32M derived: sum of 3 quarters · filed 2026-08-07 | -$1.07M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $1.97M 10-Q · filed 2026-05-08 | -$37.00K derived: sum of 2 quarters · filed 2026-05-08 | -$2.42M derived: sum of 3 quarters · filed 2026-05-08 | -$10.70M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$4.39M derived: sum of 2 quarters · filed 2026-03-13 | -$12.66M derived: sum of 3 quarters · filed 2026-03-13 | -$19.88M 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | -$2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$10.66M derived: sum of 2 quarters · filed 2025-11-07 | -$17.88M 10-Q · filed 2025-11-07 | -$16.54M derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | -$8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$15.49M 10-Q · filed 2025-08-11 | -$14.15M derived: sum of 3 quarters · filed 2025-08-11 | -$19.55M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | -$7.22M 10-Q · filed 2025-05-09 | -$5.88M derived: sum of 2 quarters · filed 2025-05-09 | -$11.28M derived: sum of 3 quarters · filed 2025-05-09 | -$19.33M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$4.06M derived: sum of 2 quarters · filed 2025-03-17 | -$12.11M derived: sum of 3 quarters · filed 2025-03-17 | -$19.76M 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | -$5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$13.45M derived: sum of 2 quarters · filed 2024-11-13 | -$21.10M 10-Q · filed 2024-11-13 | $5.21M 10-Q · filed 2023-10-26 | -$90.29M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$8.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$15.70M 10-Q · filed 2024-08-13 | $5.21M 10-Q · filed 2023-08-14 | -$84.89M derived: sum of 3 quarters · filed 2024-08-13 | -$84.89M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | -$7.65M 10-Q · filed 2024-05-13 | $411.00K 10-Q · filed 2023-05-15 | -$76.84M derived: sum of 2 quarters · filed 2024-05-13 | -$76.84M derived: sum of 3 quarters · filed 2024-05-13 | -$23.97M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | -$69.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$69.19M derived: sum of 2 quarters · filed 2024-03-27 | -$16.32M derived: sum of 3 quarters · filed 2024-03-27 | -$13.81M 10-K · filed 2024-03-27 | $55.43M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $52.87M derived: sum of 2 quarters · filed 2023-10-26 | $55.38M 10-Q · filed 2023-10-26 | $58.24M derived: sum of 4 quarters · filed 2023-10-26 | ||||
| 2022-06-30 | $52.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $55.38M 10-Q · filed 2023-08-14 | $58.24M derived: sum of 3 quarters · filed 2023-08-14 | $65.28M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-15 | $5.37M derived: sum of 2 quarters · filed 2023-05-15 | $12.41M derived: sum of 3 quarters · filed 2023-05-15 | $23.11M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $9.90M derived: sum of 2 quarters · filed 2023-03-30 | $20.61M derived: sum of 3 quarters · filed 2023-03-30 | $48.19M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $7.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $17.74M derived: sum of 2 quarters · filed 2022-11-14 | $45.32M 10-Q · filed 2022-11-14 | $72.87M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $10.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $38.28M 10-Q · filed 2022-08-15 | $65.84M derived: sum of 3 quarters · filed 2022-08-15 | $44.57M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $27.58M 10-Q · filed 2022-05-09 | $55.13M derived: sum of 2 quarters · filed 2022-05-09 | $33.87M derived: sum of 3 quarters · filed 2022-05-09 | $9.82M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $27.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $6.28M derived: sum of 2 quarters · filed 2022-03-31 | -$17.76M derived: sum of 3 quarters · filed 2022-03-31 | $9.66M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$21.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$45.31M derived: sum of 2 quarters · filed 2021-11-12 | -$17.89M 10-Q · filed 2021-11-12 | -$17.45M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | -$24.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.38M 10-Q · filed 2021-08-05 | $3.82M derived: sum of 3 quarters · filed 2021-08-05 | $18.45M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $27.42M 10-Q · filed 2021-05-06 | $27.86M derived: sum of 2 quarters · filed 2021-05-06 | $42.49M derived: sum of 3 quarters · filed 2021-05-06 | $46.15M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $440.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $15.07M derived: sum of 2 quarters · filed 2021-03-04 | $18.73M derived: sum of 3 quarters · filed 2021-03-04 | $27.39M 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $14.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $18.29M derived: sum of 2 quarters · filed 2020-11-05 | $26.95M 10-Q · filed 2020-11-05 | $31.11M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $3.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $12.32M 10-Q · filed 2020-08-06 | $16.48M derived: sum of 3 quarters · filed 2020-08-06 | $12.84M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $8.66M 10-Q · filed 2020-05-11 | $12.82M derived: sum of 2 quarters · filed 2020-05-11 | $9.18M derived: sum of 3 quarters · filed 2020-05-11 | -$63.46M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $517.00K derived: sum of 2 quarters · filed 2020-02-20 | -$72.12M derived: sum of 3 quarters · filed 2020-02-20 | -$71.32M 10-K · filed 2020-02-20 | ||||
| 2018-09-30 | -$3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$76.28M derived: sum of 2 quarters · filed 2019-11-07 | -$75.48M 10-Q · filed 2019-11-07 | -$76.99M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | -$72.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$71.84M 10-Q · filed 2019-08-01 | -$73.36M derived: sum of 3 quarters · filed 2019-08-01 | -$89.83M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | $803.00K 10-Q · filed 2019-05-02 | -$715.00K derived: sum of 2 quarters · filed 2019-05-02 | -$17.19M derived: sum of 3 quarters · filed 2019-05-02 | |||||
| 2017-12-31 | -$1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$17.99M derived: sum of 2 quarters · filed 2019-03-08 | -$11.20M 10-K · filed 2019-03-08 | |||||
| 2017-09-30 | -$16.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$9.68M 10-Q · filed 2018-11-01 | ||||||
| 2017-06-30 | $6.80M 10-Q · filed 2018-08-02 | |||||||
| 2014-06-30 | $7.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $9.42M 10-Q · filed 2014-08-07 | $13.36M derived: sum of 3 quarters · filed 2014-08-07 | $21.90M derived: sum of 4 quarters · filed 2014-08-07 | ||||
| 2014-03-31 | $1.94M 10-Q · filed 2014-05-08 | $5.87M derived: sum of 2 quarters · filed 2014-05-08 | $14.42M derived: sum of 3 quarters · filed 2014-05-08 | $18.20M derived: sum of 4 quarters · filed 2014-08-07 | ||||
| 2013-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $12.48M derived: sum of 2 quarters · filed 2014-03-14 | $16.26M derived: sum of 3 quarters · filed 2014-08-07 | $13.41M 10-K · filed 2014-03-14 | ||||
| 2013-09-30 | $8.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $12.33M derived: sum of 2 quarters · filed 2014-08-07 | $9.47M 10-Q · filed 2013-11-06 | $25.31M derived: sum of 4 quarters · filed 2014-08-07 | ||||
| 2013-06-30 | $3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $924.00K 10-Q · filed 2014-08-07 | $16.76M derived: sum of 3 quarters · filed 2014-08-07 | $33.49M derived: sum of 4 quarters · filed 2014-08-07 | ||||
| 2013-03-31 | -$2.85M 10-Q · filed 2014-05-08 | $12.98M derived: sum of 2 quarters · filed 2014-05-08 | $29.72M derived: sum of 3 quarters · filed 2014-05-08 | $30.18M derived: sum of 4 quarters · filed 2014-05-08 | ||||
| 2012-12-31 | $15.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $32.57M derived: sum of 2 quarters · filed 2014-03-14 | $33.03M derived: sum of 3 quarters · filed 2014-03-14 | $39.82M 10-K · filed 2014-03-14 | ||||
| 2012-09-30 | $16.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $17.20M derived: sum of 2 quarters · filed 2013-11-06 | $23.99M 10-Q · filed 2013-11-06 | $21.80M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-06-30 | $460.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $7.25M 10-Q · filed 2013-08-07 | $5.06M derived: sum of 3 quarters · filed 2014-03-14 | -$13.94M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-03-31 | $6.79M 10-Q · filed 2013-05-08 | $4.60M derived: sum of 2 quarters · filed 2014-03-14 | -$14.40M derived: sum of 3 quarters · filed 2014-03-14 | -$45.34M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2011-12-31 | -$2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | -$21.19M derived: sum of 2 quarters · filed 2014-03-14 | -$52.13M derived: sum of 3 quarters · filed 2014-03-14 | -$57.67M 10-K · filed 2014-03-14 | ||||
| 2011-09-30 | -$19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$49.94M derived: sum of 2 quarters · filed 2012-11-08 | -$55.48M 10-Q · filed 2012-11-08 | -$61.71M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2011-06-30 | -$30.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$36.48M 10-Q · filed 2012-08-09 | -$42.71M derived: sum of 3 quarters · filed 2013-03-15 | -$62.75M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2011-03-31 | -$5.54M 10-Q · filed 2012-05-09 | -$11.78M derived: sum of 2 quarters · filed 2013-03-15 | -$31.82M derived: sum of 3 quarters · filed 2013-03-15 | |||||
| 2010-12-31 | -$6.24M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | -$26.28M derived: sum of 2 quarters · filed 2013-03-15 | -$62.80M 10-K · filed 2013-03-15 | |||||
| 2010-09-30 | -$20.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$56.56M 10-Q · filed 2011-11-03 | ||||||
| 2010-06-30 | -$36.52M 10-Q · filed 2011-08-09 | |||||||
| 2009-12-31 | $9.80M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |